Nirmatrelvir
COVID-19 antiviral medication
Nirmatrelvir ▸ Facts ▸ Comments ▸ News ▸ Videos
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.
| 0 shares | ShareTweetSavePostSend |
You Might Like
Indian company’s oral Covid generic medicine gets WHO’s initial nodAt a time when Covid cases are surging in several nations, Hyderabad-based Hetero Group has emerged as the first pharma player in the world to bag WHO’s prequalification of medicines programme for..IndiaTimes - Published | |
Hetero emerges 1st in world to bag WHO PQ for generic version of Pfizer's Covid-19 oral drug PaxlovidPharma player Hetero Group on Monday said it has emerged as the first in the world to receive the World Health Organisation's prequalification of medicines programme (WHO-PQ) for its generic version of..IndiaTimes - Published |
| Search this site and the web: |
